洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

【ChiCTR1800016581】A Retrospective Study to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients

基本信息
登记号

ChiCTR1800016581

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2018-05-24

临床申请受理号

/

靶点

/

适应症

Total Knee Replacement

试验通俗题目

A Retrospective Study to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients

试验专业题目

A Retrospective Study to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

联系人通讯地址
临床试验信息
试验目的

to compare Cost and Effectiveness of Intravenous Patient-Controlled Analgesia (IVPCA) Morphine protocol and Preemptive Multimodal Analgesia Oral Etoricoxib and Oxycontin Protocol for Post Total Knee Replacement Patients.

试验分类
试验类型

析因分组(即根据危险因素或暴露因素分组)

试验分期

回顾性研究

随机化

N/A

盲法

N/A

试验项目经费来源

香港中文大學威爾士親王醫院麻醉與重症監護部

试验范围

/

目标入组人数

102

实际入组人数

/

第一例入组时间

1990-01-01

试验终止时间

1990-01-01

是否属于一致性

/

入选标准

Only patients with similar demographics including age, body weight ≥ 44kg,operation, anaesthesia type, medical condition, & postoperative treatment data of both groups who had attended pain management class or pre-operative anesthesia assessment clinic.;

排除标准

Patients who had not attended pain management class or pre-operative anesthesia assessment clinic, non-schedule operation, underwent bilateral TKR, severe psychological illness, active or history of drug abuse, incompliance to either treatment group or contra-indicated to the analgesics used.;

研究者信息
研究负责人姓名
试验机构

香港中文大學威爾士親王醫院麻醉與重症監護部

研究负责人电话
研究负责人邮箱
研究负责人邮编

/

联系人通讯地址
<END>

最新临床资讯

对摩熵医药数据库感兴趣,可以免费体验产品